GCM
VNDA icon

Gladius Capital Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Gladius Capital Management’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-5,500
Closed -$25.8K – 255
2024
Q3 		$25.8K Sell
5,500
-833
-13% -$4.47K ﹤0.01% 254
2024
Q2 		$35.8K Sell
6,333
-3,179
-33% -$16.4K ﹤0.01% 188
2024
Q1 		$39.1K Buy
9,512
+2,355
+33% +$9.43K 0.01% 218
2023
Q4 		$30.2K Buy
7,157
+2,083
+41% +$8.4K ﹤0.01% 282
2023
Q3 		$21.9K Buy
5,074
+114
+2% +$633 ﹤0.01% 336
2023
Q2 		$32.7K Buy
4,960
+253
+5% +$1.62K ﹤0.01% 243
2023
Q1 		$32K Buy
4,707
+1,229
+35% +$8.64K ﹤0.01% 280
2022
Q4 		$25.7K Buy
3,478
+49
+1% +$477 ﹤0.01% 304
2022
Q3 		$34K Sell
3,429
-608
-15% -$6.42K ﹤0.01% 279
2022
Q2 		$45K Buy
+4,037
New +$41.8K ﹤0.01% 259

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Gladius Capital Management's VNDA Position: Q4 2024 in Review

Gladius Capital Management sold out of Vanda Pharmaceuticals (VNDA) in Q4 2024, closing a stake of 5,500 shares — an estimated $25.8K sold.

Gladius Capital Management first reported a position in VNDA in Q2 2022 and held it in 10 quarters. The position peaked at $45K in Q2 2022. 146 funds tracked by Wall St. Rank hold VNDA as of Q4 2024.

  • Gladius Capital Management reported no remaining Vanda Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Gladius Capital Management sold 5,500 Vanda Pharmaceuticals shares in Q4 2024, an estimated $25.8K.
  • Gladius Capital Management first reported a position in Vanda Pharmaceuticals in Q2 2022 and held it in 10 quarters.
  • Gladius Capital Management's Vanda Pharmaceuticals position peaked at $45K in Q2 2022.
  • 146 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q4 2024.

Based on Gladius Capital Management's 13F filing for Q4 2024, filed 31 Jan 2025.